Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine/DFMO as Maintenance Therapy for Medulloblastoma
NCT04696029Phase 2Recruiting
- Start
- Mar 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of eflornithine in medulloblastoma. Started Mar 2021; status: recruiting.
02
Drugs
eflornithine
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04696029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696029.